EU-OPENSCREEN
EU-OPENSCREEN is a Berlin-based drug discovery platform founded in 2018 that combines high-throughput screening systems with proprietary and commercial compound libraries sourced from European chemists, serving chemistry and biology researchers across academia and industry.
- Company typePrivate
- Founded2018
- HeadquartersBerlin, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What EU-OPENSCREEN does
EU-OPENSCREEN is a Berlin-based, privately held company founded in 2018 that operates at the intersection of chemical biology and drug discovery infrastructure. According to the available firmographic data, the company combines high-throughput screening systems with a compound library that mixes commercial reagents and proprietary molecules sourced from European chemists. The implied core offering is a screening-plus-compound supply platform aimed at researchers who need both assay execution capacity and access to novel chemical matter in a single engagement. The company employs between 11 and 50 people, consistent with an early-stage platform operator.
No product catalog, pricing model, go-to-motion, customer logos, or revenue mechanics were disclosed in the source material, and the company's website returned a verification/loading page rather than substantive content. As a result, the business model cannot be characterized beyond the broad inference that revenue is generated by providing screening services and/or compound access to research clients—likely a mix of academic, biotech, and pharmaceutical users typical for European chemistry platforms. Specific revenue per employee benchmarks, contract structures, and segment mix remain unverified.
EU-OPENSCREEN firmographics
Firmographics- Name
- EU-OPENSCREEN
- Website
- https://eu-openscreen.eu
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- EU-OPENSCREEN is a Berlin-based drug discovery platform founded in 2018 that combines high-throughput screening systems with proprietary and commercial compound libraries sourced from European chemists, serving chemistry and biology researchers across academia and industry.
- Ownership category
- akta.pro rank
EU-OPENSCREEN industry classification
Industry- Product category
- Drug Discovery Screening Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)
Keywords
Where EU-OPENSCREEN is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Markets served
EU-OPENSCREEN business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
EU-OPENSCREEN product offering
Product offeringCore offering
EU-OPENSCREEN combines high-throughput screening (HTS) systems with commercial and proprietary chemicals gathered from European chemists. The company offers screening-based research services for academic and industry partners, integrating automated screening platforms with curated chemical collections to support biological assay development and early-stage compound screening.
Differentiator
Problem solved
Functional benefit
Products and services
- High-Throughput Screening (HTS) Service with Compound Library Access Service offering that combines high-throughput screening systems with access to commercial and proprietary chemical compound libraries sourced from European chemists, supporting biological assay development, hit identification, and early-stage drug discovery for academic and industrial research partners.
Companies that use EU-OPENSCREEN
Customer profileIdeal customer profiles1 record
EU-OPENSCREEN technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
EU-OPENSCREEN partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights3 records
EU-OPENSCREEN competitors and assessment
Company assessmentEmerging players
- Promega: Promega manufactures biochemical and cell-based assay reagents and screening kits widely used in HTS campaigns; it sits in EU-OPENSCREEN's supply chain and is a partial-overlap reagent/provider peer in the same drug-discovery funnel.
- Molecular Devices (Danaher): Molecular Devices supplies the automated screening platforms, plate readers, and high-content imaging systems that underpin industrial HTS workflows used across the industry, including at sites like EU-OPENSCREEN — a technology-stack peer rather than a service competitor.
Direct peers
- Evotec: Evotec (Hamburg, Germany) operates one of Europe's largest contract drug-discovery platforms, running industrial-scale high-throughput screening against proprietary and partnered compound libraries for pharma and biotech — directly comparable to EU-OPENSCREEN's HTS-plus-chemistry model.
- Enamine: Enamine (Kyiv/Estonia) maintains one of the world's largest commercially available screening collections, including the REAL database, and offers HTS-ready compound supply and hit-identification services — directly comparable as a chemistry-supplier-plus-screening infrastructure peer.
- Selvita: Selvita (Kraków, Poland) is a European CRO running integrated drug-discovery services that include HTS, medicinal chemistry, and DMPK for pharma and biotech clients — a same-region, comparable-scope peer for EU-OPENSCREEN.
Broad incumbents
- Eurofins Discovery: Eurofins Discovery (operating under Eurofins Scientific) provides commercial compound libraries and HTS, phenotypic screening, and ADME services for early-stage drug discovery — overlapping directly with EU-OPENSCREEN's compound-library plus screening offering.
- WuXi AppTec: WuXi AppTec is a global CRO/CDMO whose Discovery Services include high-throughput screening, DEL libraries, and medicinal chemistry at very large scale — competing for the same Western European and global pharma outsourcing wallet as EU-OPENSCREEN.
- Charles River Laboratories: Charles River is a global CRO whose Discovery & Safety Assessment segment offers high-throughput screening and full discovery workflow services alongside broader nonclinical and manufacturing services — an incumbent benchmark for outsourced HTS capacity in Europe and globally.
- Pharmaron (via Pharmaron/Pharmaron-UK): Pharmaron is a global CRO offering integrated discovery including in vitro pharmacology and high-throughput screening services to pharma clients worldwide — a broad incumbent competing for outsourced European discovery budgets.
Others
- LifeArc: LifeArc is a UK-based medical-research charity that runs translational drug-discovery and screening programs, historically helping to seed the European Lead Factory screening consortium — thematically aligned as a European translational screening/asset-development peer.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights4 records
Customer concentration
EU-OPENSCREEN social profiles
Digital presenceEU-OPENSCREEN financial estimates
Financial estimateRevenue estimate
Valuation estimate
EU-OPENSCREEN leadership team
Management profileNumber of profiles
EU-OPENSCREEN funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EU-OPENSCREEN M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EU-OPENSCREEN
What does EU-OPENSCREEN do?
EU-OPENSCREEN combines high-throughput screening (HTS) systems with commercial and proprietary chemicals gathered from European chemists. The company offers screening-based research services for academic and industry partners, integrating automated screening platforms with curated chemical collections to support biological assay development and early-stage compound screening.
When was EU-OPENSCREEN founded?
EU-OPENSCREEN was founded in 2018. It employs 11 to 50 people.
Where is EU-OPENSCREEN based?
EU-OPENSCREEN is headquartered in Berlin, Germany, in the Europe region.
Who are EU-OPENSCREEN's main competitors?
Emerging players on record are Promega and Molecular Devices (Danaher). Direct peers are Evotec, Enamine and Selvita. Broad incumbents are Eurofins Discovery, WuXi AppTec, Charles River Laboratories and Pharmaron (via Pharmaron/Pharmaron-UK). LifeArc is listed as an others.
Does EU-OPENSCREEN have an API?
No public API is recorded for EU-OPENSCREEN.
What industry is EU-OPENSCREEN in?
EU-OPENSCREEN's product category is Drug Discovery Screening Services. Its primary akta.pro industry code is HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening). Its NAICS code is 541714 and its SIC code is 8731.